Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
4.118
-0.312 (-7.05%)
At close: Nov 4, 2026, 4:00 PM EST
3.895
-0.223 (-5.41%)
After-hours: Nov 4, 2026, 7:30 PM EST
Revelation Biosciences Employees
Revelation Biosciences had 9 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes Revelation Biosciences the 40,532nd largest employer in the world and 6,166th in the United States.
Employees
9
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,133,553
Market Cap
2.34M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 9 | 0 | - | 8 | 1 |
| Dec 31, 2024 | 9 | -1 | -10.00% | 8 | 1 |
| Dec 31, 2023 | 10 | 4 | 66.67% | 9 | 1 |
| Dec 31, 2022 | 6 | - | - | 6 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| HCW Biologics | 35 |
| Calidi Biotherapeutics | 29 |
| Curis | 24 |
| NeuroSense Therapeutics | 17 |
| VivoSim Labs | 15 |
| BioRestorative Therapies | 14 |
| Silo Pharma | 3 |
REVB News
- 16 days ago - Revelation Biosciences Inc trading halted, news pending - TheFly
- 19 days ago - Revelation Biosciences announces 1-for-7 reverse stock split - TheFly
- 19 days ago - Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026 - Business Wire
- 2 months ago - Revelation Biosciences selects Avance Clinical as CRO for Phase 2/3 Titan Study - TheFly
- 2 months ago - Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study - Business Wire
- 3 months ago - Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026 - Accesswire
- 3 months ago - Revelation Biosciences Quarterly report: Q2 2026 - Filings
- 3 months ago - Revelation Biosciences Earnings release: Q2 2026 - Filings